Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · IEX Real-Time Price · USD
39.73
-2.56 (-6.05%)
At close: Jul 2, 2024, 4:00 PM
41.80
+2.07 (5.21%)
After-hours: Jul 2, 2024, 7:06 PM EDT
Company Description
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Soleno Therapeutics, Inc.
| Country | United States |
| IPO Date | Nov 13, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Dr. Anish Bhatnagar M.D. |
Contact Details
Address: 203 Redwood Shores Parkway, Suite 500 Redwood City, California 94065 United States | |
| Phone | 650-213-8444 |
| Website | soleno.life |
Stock Details
| Ticker Symbol | SLNO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001484565 |
| CUSIP Number | 834203200 |
| ISIN Number | US8342033094 |
| Employer ID | 77-0523891 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anish Bhatnagar M.D. | President, Chief Executive Officer, Chief Operating Officer and Director |
| James H. MacKaness | Chief Financial Officer |
| Patricia C. Hirano | Vice President of Regulatory Affairs |
| Dr. Neil M. Cowen M.B.A., Ph.D. | Senior Vice President of Drug Development |
| Meredith Manning M.B.A. | Chief Commercial Officer |
| Kristen Yen M.S. | Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2024 | 144 | Filing |
| Jun 28, 2024 | 8-K | Current Report |
| Jun 20, 2024 | 8-K | Current Report |
| Jun 6, 2024 | 8-K | Current Report |
| May 10, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| May 6, 2024 | 424B5 | Filing |
| May 2, 2024 | 424B5 | Filing |
| May 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |